EP3755319A1 - Composés et compositions pour le traitement de troubles musculaires - Google Patents

Composés et compositions pour le traitement de troubles musculaires

Info

Publication number
EP3755319A1
EP3755319A1 EP19756654.0A EP19756654A EP3755319A1 EP 3755319 A1 EP3755319 A1 EP 3755319A1 EP 19756654 A EP19756654 A EP 19756654A EP 3755319 A1 EP3755319 A1 EP 3755319A1
Authority
EP
European Patent Office
Prior art keywords
epicatechin
bone
composition
muscle
weakness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19756654.0A
Other languages
German (de)
English (en)
Other versions
EP3755319A4 (fr
Inventor
George F. Schreiner
Guillermo Ceballos
Sundeep Dugar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epirium Bio Inc
Original Assignee
Epirium Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/900,533 external-priority patent/US20180193306A1/en
Application filed by Epirium Bio Inc filed Critical Epirium Bio Inc
Publication of EP3755319A1 publication Critical patent/EP3755319A1/fr
Publication of EP3755319A4 publication Critical patent/EP3755319A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring

Abstract

La présente invention concerne des composés et des compositions et leurs applications en tant que produits pharmaceutiques pour réduire une lésion osseuse, une faiblesse osseuse ou une perte osseuse ou pour empêcher des fractures osseuses. L'invention concerne l'administration à un sujet d'une dose thérapeutiquement efficace de (+)-épicatéchine et/ou de (-)-épicatéchine, ou d'un dérivé d'épicatéchine pour réduire une lésion osseuse, une faiblesse osseuse ou une perte osseuse ou pour empêcher des fractures osseuses.
EP19756654.0A 2018-02-20 2019-02-20 Composés et compositions pour le traitement de troubles musculaires Withdrawn EP3755319A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/900,533 US20180193306A1 (en) 2012-03-23 2018-02-20 Compounds and compositions for the treatment of muscular disorders and bone disorders
PCT/US2019/018730 WO2019164914A1 (fr) 2018-02-20 2019-02-20 Composés et compositions pour le traitement de troubles musculaires

Publications (2)

Publication Number Publication Date
EP3755319A1 true EP3755319A1 (fr) 2020-12-30
EP3755319A4 EP3755319A4 (fr) 2021-12-01

Family

ID=67687368

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19756654.0A Withdrawn EP3755319A4 (fr) 2018-02-20 2019-02-20 Composés et compositions pour le traitement de troubles musculaires

Country Status (8)

Country Link
EP (1) EP3755319A4 (fr)
JP (1) JP2021514380A (fr)
CN (1) CN111989098A (fr)
AU (1) AU2019224003A1 (fr)
BR (1) BR112020016923A2 (fr)
CA (1) CA3091892A1 (fr)
IL (1) IL276786A (fr)
WO (1) WO2019164914A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170430A1 (fr) 2011-06-06 2012-12-13 Cardero Therapeutics, Inc. Méthodes et compositions pour le traitement de la toxicité mitochondriale
US10898465B2 (en) 2016-06-21 2021-01-26 Epirium Bio Inc. Utility of (+) epicatechin and their analogs
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
WO2024036225A1 (fr) * 2022-08-10 2024-02-15 Epirium Bio Inc. Épicatéchine pour l'inhibition de la toxicité du glutamate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072714A2 (fr) * 2002-02-21 2003-09-04 Wyeth Domaine follistatine contenant des proteines
JP2004161669A (ja) * 2002-11-13 2004-06-10 Ito En Ltd 骨形成促進剤
CN100361655C (zh) * 2005-09-05 2008-01-16 中山大学 (-)-表没食子儿茶素没食子酸酯-钙络合物固体分散体及其制备方法与应用
CA2690685A1 (fr) * 2007-06-20 2008-12-24 Galapagos N.V. Cibles et composes moleculaires utiles dans le traitement de maladies degeneratives des os et des articulations, et procedes pour les identifier
US9119818B2 (en) * 2008-05-14 2015-09-01 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders
JP2010095474A (ja) * 2008-10-17 2010-04-30 Ito En Ltd カルシウム吸収促進組成物及びカルシウム吸収促進飲食物
KR101096574B1 (ko) * 2008-12-12 2011-12-20 에이치 엘 지노믹스(주) 유럽종 포도의 씨 추출물을 함유하는 골다공증 예방 또는 치료용 약학 조성물
JP2011006355A (ja) * 2009-06-25 2011-01-13 Ito En Ltd 骨密度改善組成物及び飲食物
JP2013051920A (ja) * 2011-09-05 2013-03-21 Ishikawa Prefectural Public Univ Corp 骨密度強化補助食品
WO2013142816A1 (fr) * 2012-03-23 2013-09-26 Cardero Therapeutics, Inc. Composés et compositions pour le traitement d'affections musculaires
EP2903458B1 (fr) * 2012-10-04 2018-09-05 Abbott Laboratories Méthodes d'amélioration de l'effet de l'egcg sur l'atténuation de la perte musculaire squelettique
CA3057129C (fr) * 2014-06-16 2021-07-20 Unigen, Inc. Compositions et methodes de prise en charge ou d'attenuation de troubles osseux, de troubles du cartilage ou des deux

Also Published As

Publication number Publication date
IL276786A (en) 2020-10-29
WO2019164914A1 (fr) 2019-08-29
BR112020016923A2 (pt) 2020-12-15
CN111989098A (zh) 2020-11-24
CA3091892A1 (fr) 2019-08-29
EP3755319A4 (fr) 2021-12-01
AU2019224003A1 (en) 2020-10-08
JP2021514380A (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
US9901564B2 (en) Compounds and compositions for the treatment of muscular disorders
US11273144B2 (en) Compounds and compositions for the treatment of muscular disorders and bone disorders
US20220105117A1 (en) Compositions comprising nicotinamide riboside and a urolithin
AU2019224003A1 (en) Compounds and compositions for the treatment of muscular disorders
AU2006227949B2 (en) Composition and method for modulating hydrogen ion physiology
AU2007275561B2 (en) Improvement of arginase levels/activity
US20220378731A1 (en) Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column
KR20100094485A (ko) 아미노산 조성물을 함유하는 피로 방지제
WO2020127183A1 (fr) Nouveaux composés de polyméthoxyflavone pour la modulation du muscle squelettique, procédés et utilisations de ceux-ci
JP7271016B2 (ja) 骨損失疾患の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）および副甲状腺ホルモンを含む組成物の用途
US20230255238A2 (en) Compositions and methods using at least one of oleuropein or a metabolite thereof to treat or prevent muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise
CN116075304A (zh) 含有烟酰胺和维生素b6的组合物以及使用此类组合物来治疗肌肉减少症和虚弱的方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200915

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211103

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20211027BHEP

Ipc: A61K 33/06 20060101ALI20211027BHEP

Ipc: A61K 31/593 20060101ALI20211027BHEP

Ipc: C07D 311/74 20060101ALI20211027BHEP

Ipc: C07D 311/62 20060101ALI20211027BHEP

Ipc: A61P 19/10 20060101ALI20211027BHEP

Ipc: A61P 19/08 20060101ALI20211027BHEP

Ipc: A61K 31/353 20060101AFI20211027BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220604